Abstract
The treatment of bacterial skin infections has become challenging with the evolution of resistant species. As common antibiotics are losing efficacy, there is a pressing need for the discovery of new antibacterial agents. Only several systemic antibiotics have been approved for the treatment of skin infections in recent years. The expanding repertoire includes novel compounds structurally based on existing antibiotic classes, such as the glycopeptides, cephalosporins, and glycylcyclines. Antibiotics with completely unique mechanisms of action are being developed as members of the lipoprotein, oxazolidonone, and streptogramin classes. Most of these drugs require intravenous administration that limits their use. Future development should focus on more accessible routes of antibiotic administration, including oral, inhaled, or transdermal formulations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
